Ketamine for Anxiety Disorders

77 papers and 20 clinical trials exploring ketamine as a treatment for anxiety disorders.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

77 papers
Open Accessindividual

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program

In a naturalistic open‑label study of 185 adults with severe treatment‑resistant depression, twice‑weekly individually titrated oral esketamine for six weeks significantly reduced depressive symptoms (HDRS‑17 mean 21.2→15.8, p<0.001) with MCID 47.1%, response 26.8% and remission 15.6%, and a low dropout rate (7.6%). Treatment was generally well tolerated with frequent but manageable side effects and no significant urinary or cognitive adverse effects, suggesting oral esketamine is a safe, patient‑friendly option with effectiveness comparable to other administration routes.

Published
Journal
Journal of Psychopharmacology
Authors
Kamphuis, J., Schoevers, R. A., Smith-Apeldoorn, S. Y., Spijker, J., van der Meij, A., Veraart, J. K. E.
Open Accessindividual

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study

In this multisite, double-blind RCT in treatment‑resistant depression, subcutaneous racemic ketamine given twice weekly for 4 weeks at flexible, response‑guided doses (0.5–0.9 mg/kg) produced a significant short‑term reduction in anxiety (HAM‑A) versus midazolam, whereas a fixed low dose (0.5 mg/kg) did not. The anxiolytic effect was mediated by antidepressant response and was not maintained 4 weeks after treatment end.

Published
Journal
British Journal of Psychiatry
Authors
Alonzo, A., Barton, D., Baune, B. T., Berk, M., Carter, G. T., Chatterton, M. L., Dong, V., Fitzgerald, P. B., Glozier, N., Glue, P., Hackett, M., Hadzi-Pavlovic, D., Hood, S., Loo, C., Martin, D., Mihalopoulos, C., Mills, N. T., Mitchell, P. B., Nikolin, S., Rodgers, A., Sarma, S., Somogyi, A. A.
Open Accessindividual

Randomized Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression - the BEDROC Study

In this phase 2 randomised, placebo‑controlled enrichment study, extended‑release oral ketamine tablets (R‑107) given twice weekly maintained antidepressant response in treatment‑resistant depression, with the 180 mg dose producing a significant 13‑week MADRS improvement versus placebo (least‑square mean difference −6.1, P = 0.019). R‑107 was generally well tolerated with minimal blood‑pressure, sedation or dissociation effects, showed a dose–response reduction in relapse rates, and most dosing was performed at home.

Published
Journal
Nature Medicine
Authors
Fam, J., Glue, P., Lane, H. Y., Loo, C., Surnam, P., Young, A.
Paywallindividual

Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial

This placebo-controlled trial (n=54) investigates the efficacy and safety of esketamine (iv, 17.5mg, 3x) in adolescents suffering from depression (MDD) and suicidal ideation (SI). It shows significant reductions in Columbia Suicide Severity Rating Scale (C-SSRS) Ideation and Intensity scores and Montgomery-Åsberg Depression Rating Scale (MADRS) scores in the esketamine group compared to the midazolam (placebo) group at day six, with maintained antisuicidal and antidepressant responses at four weeks post-treatment.

Published
Journal
Child and Adolescent Psychiatry
Authors
Chao, Z., Fu, L., Hu, Z., Lan, X-F., Li, W., Liu, H., Ning, Y-P., Wang, C., Ye, Y., Zhang, F., Zhou, Y.

Clinical Trials

20 trials

Explore further

Search all Ketamine papers Search all Anxiety Disorders trials Full Ketamine profile Full Anxiety Disorders profile
Ketamine for Anxiety Disorders — Research Papers & Clinical Trials | Blossom